» Articles » PMID: 35079454

Metastasis of Renal Cell Carcinoma to Spinal Hemangioblastoma in a Patient with Von Hippel-Lindau Disease: A Case Report

Overview
Journal NMC Case Rep J
Specialty Neurology
Date 2022 Jan 26
PMID 35079454
Authors
Affiliations
Soon will be listed here.
Abstract

von Hippel-Lindau (VHL) disease is characterized by neoplastic and cystic lesions, such as central nervous system (CNS) hemangioblastoma and clear cell renal cell carcinoma (RCC), arising in multiple organs. Here, we report a case of an RCC that metastasized to a spinal hemangioblastoma in a patient diagnosed with VHL disease. This is a unique case study because visceral neoplasms rarely metastasize to the CNS. The patient had undergone posterior fossa surgery for the removal of hemangioblastomas in the right cerebellar hemisphere as a child. He was diagnosed with RCC at the age of 20 years, and he underwent partial nephrectomy at the age of 35 years. The patient underwent surgical removal of a spinal tumor from Th8, which was also diagnosed as a hemangioblastoma at the age of 40. However, the residual spinal tumor rapidly regrew within 1.5 years. A second surgery was performed due to progressive leg motor weakness. The resected tumor from the second surgery had two distinct components between the tumor center and the margin. Immunohistochemistry of CD10, PAX 8, and inhibin A demonstrated the predominant region of the tumor was RCC. Pathological findings confirmed tumor-to-tumor metastasis of the RCC migrating into residual spinal hemangioblastoma. It can be challenging to distinguish hemangioblastoma from RCC in neuroimaging. We suggest that tumor-to-tumor metastasis should be considered as a differential diagnosis if benign tumors grow rapidly, even if the pathological diagnosis does not initially confirm malignancy. The biological mechanisms of RCC migrating into residual hemangioblastoma are discussed.

Citing Articles

Unraveling Tumor-to-Tumor Metastasis: Insights into Pathogenesis, Diagnostic Challenges, and Treatment Modalities.

Mei W, Zhang D Biologics. 2025; 19:43-58.

PMID: 40041727 PMC: 11878131. DOI: 10.2147/BTT.S505950.


Supratentorial Collision Tumor of Hemangioblastoma and Metastatic Clear Cell Renal Cell Carcinoma in a Patient with von Hippel-Lindau Disease.

Luo W, Sun C, Yu S Case Rep Oncol. 2023; 16(1):919-929.

PMID: 37900808 PMC: 10601739. DOI: 10.1159/000531876.

References
1.
Wilhelm S, Adnane L, Newell P, Villanueva A, Llovet J, Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-40. DOI: 10.1158/1535-7163.MCT-08-0013. View

2.
Erdogan H, Aydin M, Tasdemiroglu E . Tumor-to-tumor metastasis of the central nervous system. Turk Neurosurg. 2014; 24(2):151-62. DOI: 10.5137/1019-5149.JTN.8317-13.1. View

3.
Richter B, Harinath L, Pu C, Stabingas K . Metastatic spread of systemic neoplasms to central nervous system tumors: review of the literature and case presentation of esophageal carcinoma metastatic to meningioma. Clin Neuropathol. 2016; 36 (2017)(2):60-65. DOI: 10.5414/NP300980. View

4.
Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T . Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer. 2002; 34(1):58-68. DOI: 10.1002/gcc.10054. View

5.
Hamazaki S, Nakashima H, Matsumoto K, Taguchi K, Okada S . Metastasis of renal cell carcinoma to central nervous system hemangioblastoma in two patients with von Hippel-Lindau disease. Pathol Int. 2002; 51(12):948-53. DOI: 10.1046/j.1440-1827.2001.01298.x. View